HTR3D

5-hydroxytryptamine receptor 3D (5-HT3-D) (5- · Q70Z44 · HTR3D on Sugi Atlas →

68,030 patent compounds predicted against HTR3D, 45,313 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tropisetron (SCHEMBL18297)	1.00	7/20
Tropisetron (SCHEMBL18299)	1.00	7/20
Tropisetron (SCHEMBL133873)	0.98	7/20
Dolasetron (SCHEMBL42063)	0.72	7/20
Dolasetron (SCHEMBL42064)	0.72	7/20
Dolasetron (SCHEMBL42065)	0.72	7/20
Dolasetron (SCHEMBL41145)	0.65	7/20
Dolasetron (SCHEMBL41146)	0.65	7/20
Mirisetron (SCHEMBL194840)	0.59	7/20
Mirisetron (SCHEMBL194841)	0.59	7/20
Mirisetron (SCHEMBL121861)	0.55	6/20
Mirisetron (SCHEMBL121862)	0.55	6/20
Phenylpiperazine (SCHEMBL24889)	1.00	5/20
Phenylpiperazine (SCHEMBL55125)	1.00	5/20
SCHEMBL166140	1.00	5/20
SCHEMBL232655	0.61	5/20
SCHEMBL59331	0.61	5/20
SCHEMBL164098	0.56	5/20
SCHEMBL221254	0.55	5/20
Noxiptiline (SCHEMBL49824)	0.52	5/20

Clinical trials — most relevant to HTR3D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cariprazine Versus Placebo for Social Anxiety Disorder	PHASE4	COMPLETED
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder	PHASE4	COMPLETED
Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease	PHASE4	NOT_YET_RECRUITING
Vortioxetine for the Treatment of Hoarding Disorder	PHASE3	WITHDRAWN
Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
5HT2CR Balance in Brain Connectivity in Cocaine Dependence	PHASE1/PHASE2	COMPLETED
Lorcaserin Intra Venous Cocaine Effects	PHASE1/PHASE2	UNKNOWN
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	PHASE1/PHASE2	RECRUITING
The Neurobiological Effect of 5-HT2AR Modulation	PHASE1	RECRUITING
PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY	PHASE1	COMPLETED
GSK618334 Repeat Dose Study	PHASE1	COMPLETED
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment	nan	COMPLETED
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling	nan	UNKNOWN
PET Whole Body Distribution Studies Using [11C]CUMI	nan	COMPLETED
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors	nan	COMPLETED
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.	nan	COMPLETED
Prucalopride and Cognition in Recovered Depression	nan	COMPLETED
Hormonal Causes of Menstrual-Related Mood Disorders	nan	COMPLETED
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI	nan	COMPLETED
Serotonin in Alcoholism	nan	COMPLETED
The Role of Sex Steroids and Serotonin Brain Dynamics in Perinatal Mental Health	nan	COMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Investigating the Neuropsychological Effects of 5-HT2a Antagonism	nan	RECRUITING
Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)	nan	RECRUITING
Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging	nan	COMPLETED
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality	nan	SUSPENDED
Trazodone and the Risk of Serious Adverse Events	nan	COMPLETED
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HTR3D binder may also engage these)

Protein	Name	Similarity
Q9D159	—	0.949	Q9D159 →
Q96LM9	—	0.946	Q96LM9 →
Q5FW56	—	0.943	Q5FW56 →
Q3UIW8	—	0.943	Q3UIW8 →
Q8K451	—	0.942	Q8K451 →
Q68UT4	—	0.941	Q68UT4 →
Q7Z443	—	0.941	Q7Z443 →
P51172	—	0.941	P51172 →
Q6PCP7	—	0.941	Q6PCP7 →
Q8N2C3	—	0.940	Q8N2C3 →
Q8NFN8	—	0.940	Q8NFN8 →
Q6IPT2	—	0.939	Q6IPT2 →
Q6ZST4	—	0.939	Q6ZST4 →
Q8IZJ4	—	0.939	Q8IZJ4 →
Q7Z5J1	—	0.939	Q7Z5J1 →
Q2T9K0	—	0.938	Q2T9K0 →
Q6DHY5	—	0.938	Q6DHY5 →
Q96ET8	—	0.937	Q96ET8 →
Q9BT76	—	0.937	Q9BT76 →
Q8CJ11	—	0.937	Q8CJ11 →
Q9P2K9	—	0.937	Q9P2K9 →
Q6AZ51	—	0.936	Q6AZ51 →
Q9BQI9	—	0.936	Q9BQI9 →
A0A087X179	—	0.936	A0A087X179 →
Q5VTJ3	—	0.936	Q5VTJ3 →
PLAAT5	Phospholipase A and acyltransferase 5	0.935	landscape →
D4A693	—	0.935	D4A693 →
Q9H1B4	—	0.935	Q9H1B4 →
A0A087WXS9	—	0.935	A0A087WXS9 →
Q8TCY5	—	0.935	Q8TCY5 →